Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of CG 8020 and CG 2505 in Patients With Nonresectable or Metastatic Pancreatic Cancer

NCT00245362 is registered in ClinicalTrials.gov with Cell Genesys as lead sponsor.

NCT NCT00245362
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00245362 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of CG 8020 and CG 2505 in Patients With Nonresectable or Metastatic Pancreatic Cancer
Lead sponsor
Cell Genesys
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2002
Completion date
June 30, 2004
Enrollment
50
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic pancreatic cancer, nonresectable pancreatic cancer